Delivery Order SPE2DB24D1205-SPE2DB25FCXMM
- Not listed
- The Defense Logistics Agency awarded a $69,112.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BIMZELX 160 mg/ml auto-injectors, with an ultimate completion date of August 5, 2025. This competitive award, which was not set-aside, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $11,394.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BIMZELX 160 mg/ml auto-injector product, with an ultimate completion date of August 6, 2025. This competitively awarded contract, with no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $27,466.85 to AmerisourceBergen Drug Corp for BIMZELX 160 mg/ml autoinjectors. This firm fixed-price, competitively awarded contract was executed on May 27, 2025, with an ultimate completion date of May 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency valued at $60,638.45 for BIMZELX 160 mg/mL auto-injector medication. Awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, this firm fixed price delivery order was competitively awarded with no set-aside designation. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a delivery order valued at $74,689.95 to AmerisourceBergen Drug Corp for BIMZELX 160 mg/mL auto-injector supplies. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 1, 2025, and performance location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, serves as a critical vendor for federal military and veteran healthcare systems through the...
- The Defense Logistics Agency awarded a $10,858.52 delivery order to AmerisourceBergen Drug Corp for BIMZELX 320 mg/2 ml auto-injector pharmaceutical product on July 25, 2025, with final delivery scheduled for July 28, 2025. This firm fixed-price, non-set-aside contract was competitively awarded and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal healthcare vendor that...
- The Defense Logistics Agency awarded a delivery order valued at $10,250.68 to AmerisourceBergen Drug Corp for BIMZELX 160 mg/ml autoinjector on August 29, 2025, with completion expected by September 2, 2025. This competitively awarded, firm fixed-price contract involves pharmaceutical delivery to support federal medical procurement needs. The contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as...
- This delivery order, valued at $147,823.27, was awarded on September 18, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of BIMZELX 160 MG/ML auto-injectors. The award represents a firm fixed-price contract with no set-aside designation, indicating the vendor was selected through open competitive procurement. Performance will be completed by September 19, 2025, at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $35K to AmerisourceBergen Drug Corp for BIMZELX 320 mg/2 mL auto-injector pharmaceutical products. This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by September 15, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken....
- The Defense Logistics Agency awarded a delivery order valued at $43,770.93 to AmerisourceBergen Drug Corp for the supply of BIMZELX 320 mg/2 mL auto-injector units. The contract, which was competitively awarded without set-aside restrictions, carries a firm fixed price structure and an ultimate completion date of August 18, 2025. Performance of this delivery order will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXMMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,392.51 to AmerisourceBergen Drug Corp for the supply of BIMZELX 160 mg/ml autoinjectors. This is a firm fixed price, non-set-aside contract with a completion date of June 9, 2025, and represents a pediatric immunology medication delivery to support military healthcare needs. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's demonstrated capability to fulfill competitive federal medical procurement requirements, combined with its extensive portfolio of specialty and brand-name pharmaceutical deliveries, positions it as a critical vendor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 6/6/25 |